Is it time to Buy before this week’s earning report Intersect ENT (NASDAQ:XENT)

Earnings results for Intersect ENT (NASDAQ:XENT)

Intersect ENT, Inc. is expected* to report earnings on 05/10/2021 before market open. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.42. The reported EPS for the same quarter last year was $-0.54.

Intersect ENT last released its quarterly earnings results on March 8th, 2021. The medical equipment provider reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.22. The firm earned $28.20 million during the quarter, compared to analyst estimates of $27.83 million. Its revenue was down 11.3% on a year-over-year basis. Intersect ENT has generated ($1.37) earnings per share over the last year. Intersect ENT has confirmed that its next quarterly earnings report will be published on Monday, May 10th, 2021.

Analyst Opinion on Intersect ENT (NASDAQ:XENT)

7 Wall Street analysts have issued ratings and price targets for Intersect ENT in the last 12 months. Their average twelve-month price target is $25.67, predicting that the stock has a possible upside of 22.63%. The high price target for XENT is $32.00 and the low price target for XENT is $19.00. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of “Hold.”

Intersect ENT has received a consensus rating of Hold. The company’s average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings. According to analysts’ consensus price target of $25.67, Intersect ENT has a forecasted upside of 22.6% from its current price of $20.93. Intersect ENT has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Intersect ENT (NASDAQ:XENT)

Intersect ENT does not currently pay a dividend. Intersect ENT does not have a long track record of dividend growth.

Insiders buying/selling: Intersect ENT (NASDAQ:XENT)

In the past three months, Intersect ENT insiders have not sold or bought any company stock. Only 3.50% of the stock of Intersect ENT is held by insiders. 84.32% of the stock of Intersect ENT is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Intersect ENT (NASDAQ:XENT

Earnings for Intersect ENT are expected to grow in the coming year, from ($1.88) to ($1.20) per share. The P/E ratio of Intersect ENT is -10.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Intersect ENT is -10.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Intersect ENT has a P/B Ratio of 5.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here